Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPA8 | P11142 | 6/20 | 0.74 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.74 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SLC28A2 | O43868 | 7/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1661019 | 1.00 | HSPA8 (0.74) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL14380122 | 1.00 | HSPA8 (0.74) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL11574082 | 0.97 | HSPA8 (0.73) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL11574099 | 0.97 | HSPA8 (0.73) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6758944 | 0.96 | HSPA8 (0.72) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6758942 | 0.96 | HSPA8 (0.72) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6762435 | 0.90 | FBP1 (0.79) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL13127208 | 0.90 | HSPA8 (0.80) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6762443 | 0.90 | FBP1 (0.79) | HSPA8HSPA5RXFP1FBP1SLC28A2 | |
| SCHEMBL6763143 | 0.90 | HSPA8 (0.80) | HSPA8HSPA5RXFP1FBP1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110262442-A1 | COMPOSITIONS FOR TREATING CNS DISORDERS | ADENIOS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-03-05 | — | — | US | disclosed |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY INC (US) | 2022-02-10 | — | — | US | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2021-05-13 | — | — | US | disclosed |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTONOMY, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9132087-B2 | Auris formulations for treating otic diseases and conditions | OTONOMY, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| WO-2015013653-A1 | GENERATING DEFINITIVE ENDODERM AND PANCREATIC PROGENITOR CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | OTONOMY, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| EP-2490722-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | Otonomy, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049960-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049958-A2 | MODULATION OF GEL TEMPERATURE OF POLOXAMER-CONTAINING FORMULATIONS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTONOMY, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210138069-A1 | TRIGLYCERIDE OTIC FORMULATIONS AND USES THEREOF | CETP, LIPA, APOB | HSPA8 1821/4885HSPA5 1952/4885RXFP1 2815/4885 |
| US-11332716-B2 | Methods and compositions for producing pancreatic beta cells | IAPP, ALPG, AMY2A | HSPA8 3693/4885HSPA5 1445/4885RXFP1 2784/4885 |
| US-20220040096-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-11123286-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | HSPA8 1006/4885HSPA5 1875/4885RXFP1 265/4885 |
| US-20090306225-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-20160095902-A1 | Auris Formulations for Treating Otic Diseases and Conditions | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-11123285-B2 | Auris formulations for treating OTIC diseases and conditions | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-11918653-B2 | Triglyceride otic formulations and uses thereof | CETP, LIPA, APOB | HSPA8 1821/4885HSPA5 1952/4885RXFP1 2815/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-20120277199-A1 | Modulation of Gel Temperature of Poloxamer-Containing Formulations | PTGIR, HSPH1, HSP90AA1 | HSPA8 15/4885HSPA5 446/4885RXFP1 2585/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | HSPA8 1036/4885HSPA5 3165/4885RXFP1 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.